Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is poised for long-term success as they continue to invest in new product launches and experience growth in their Pharmaceutical and Medical Devices segments. Despite legal challenges, their strong pipeline and disciplined approach to capital allocation make them a top performer in the MedTech industry. With a commitment to sustainability and an optimistic outlook for revenue and EPS, JNJ is a prudent investment for those seeking long-term growth and stability.

Bears say

Johnson & Johnson is a well-diversified healthcare company that has recently undergone restructuring and divestment to focus on its innovative medicine and medtech divisions. Despite potential for growth in key areas such as vision and cardiovascular products, there are several risks including loss of exclusivity for key drugs, potential challenges in the MedTech division, and ongoing litigations that could disrupt the company's operations. Furthermore, there is uncertainty surrounding the success of its sustainability initiatives and potential challenges with M&A and integration.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $244.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $244.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.